Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07269041 · ClinicalTrials.gov registry record · Phase 1
Immune Tolerance Induction After Liver Transplantation
A Phase 1 study of End Stage Liver DIsease and Liver Transplantation, sponsored by University of California, Los Angeles.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT07269041 is a Phase 1 study of End Stage Liver DIsease and Liver Transplantation that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 12 participants, below the 491-participant average among 16 other End Stage Liver DIsease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07269041, a Phase 1 study of End Stage Liver DIsease and Liver Transplantation, is actively recruiting participants, sponsored by University of California, Los Angeles.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial is being conducted to help liver transplant recipients safely discontinue toxic immunosuppressive drugs years after surgery. Lifelong use of these drugs is the current standard, but they come with life-threatening side effects. UCLA has pioneered this "Delayed Tolerance" approach, achieving success in numerous kidney recipients now living drug-free. The process uses a conditioning regimen followed by donor stem cell infusion to retrain the immune system to accept the liver as "self."
Conditions Studied
Interventions
- BIOLOGICAL Donor Hematopoietic Stem and Progenitor Cell Infusion
Study Locations (1)
California
- UCLA Health 200 Medical Plaza - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-02-20 |
| Est. Completion | 2033-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07269041
The ClinicalTrials.gov registry entry for NCT07269041 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 491-participant average among 16 other End Stage Liver DIsease trials with a reported enrollment target (98% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with End Stage Liver DIsease appearing as the primary indexed condition, and to 1 intervention - of which Donor Hematopoietic Stem and Progenitor Cell Infusion is the first listed.
NCT07269041 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07269041 about?
NCT07269041 is a clinical study titled "Immune Tolerance Induction After Liver Transplantation". This clinical trial is being conducted to help liver transplant recipients safely discontinue toxic immunosuppressive drugs years after surgery. Lifelong use of these drugs is the current standard, but they come with life-threatening side effects. UCLA has pioneered this "Delayed Tolerance" approach...
What is the current status of trial NCT07269041?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2026-02-20. Estimated completion is 2033-01.
What conditions does trial NCT07269041 study?
This clinical trial studies the following conditions: End Stage Liver DIsease, Liver Transplantation, Immune Tolerance, Chimerism, Immune Tolerance/Drug Effects.
What interventions are being tested in trial NCT07269041?
The interventions under investigation include: Donor Hematopoietic Stem and Progenitor Cell Infusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT07269041?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07269041 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Liver DIsease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of SIPLIZUMAB in AILD and LT Patients
RECRUITING · Phase 1
-
Disparities Among Liver Transplant Patients
RECRUITING
-
HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease
RECRUITING · NA
-
Adverse Outcomes and Mortality in Liver Transplant
RECRUITING · NA
-
LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease
RECRUITING · NA
-
Testing LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.